Overview
MDD & ADHD Market Opportunity
The global market for Adult Attention Deficit Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD) presents a compelling growth opportunity driven by rising prevalence, unmet patient needs, and a lack of safe, all-natural treatment options.
While advancements in diagnostics and treatment access have improved, both the ADHD and MDD markets are underserved—particularly in the space of non-addictive, FDA-approved natural therapies. Today’s patients and healthcare providers are seeking effective alternatives to conventional synthetic medications. AiBtl BioPharma’s all-natural drug candidates, ABV-1505 (ADHD) and ABV-1504 (MDD), are protected by patents until 2040 and uniquely positioned to address this demand.
ADHD Market Opportunity
ADHD remains one of the most common neurodevelopmental disorders globally, impacting both children and adults.
- Market Size: Valued at $16.2 billion in 2023, the global ADHD market is expected to grow to $30.6 billion by 2032, reflecting a 7.3% CAGR (Source: Polaris Market Research).
- Growth Drivers: Increased awareness, improved diagnosis, and the growing adoption of both stimulant and non-stimulant therapies.
- Market Challenges: Underdiagnosis and rising drug prices are driving demand for safer, more affordable alternatives.
- Our Solution: ABV-1505, an all-natural, patent-protected therapy, is designed to provide a non-addictive, plant-based solution for ADHD patients seeking effective treatment beyond traditional stimulant medications.
MDD Market Opportunity
Major Depressive Disorder (MDD) is a global mental health crisis and a leading contributor to disability worldwide.
- Global Impact: Over 280 million people affected globally; projected to become the #1 cause of disability by 2030.
- U.S. Mental Health Crisis: Nearly 60 million U.S. adults report mental illness annually, with over 13 million experiencing suicidal thoughts.
- Treatment Gap: More than 50% of MDD patients do not receive adequate care, highlighting a critical need for accessible, safer alternatives (Source: University of Queensland, MedicalXpress).
- Our Solution: ABV-1504, our all-natural MDD treatment, offers a unique, non-synthetic option backed by promising clinical data and a differentiated mechanism of action.
Advancing Mental Health Therapies Through Innovation
AiBtl BioPharma is committed to pioneering treatments in mental health through innovative science and a patient-centered approach. Our focus is on developing safe, effective therapies that address unmet medical needs in anxiety, depression, and other CNS disorders.
